Cacna1D Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CACNA1D Protein | |
|---|---|
| Protein Name | Calcium Voltage-Gated Channel Subunit Alpha1 D (Cav1.3) |
| Gene | CACNA1D |
| UniProt ID | Q01658 |
| Molecular Weight | ~245 kDa |
| Subcellular Localization | Cell membrane, dendritic shafts, presynaptic terminals |
| Protein Family | Voltage-gated calcium channel (Cav1) family |
CACNA1D encodes the alpha-1D subunit of L-type voltage-gated calcium channels, known as Cav1.3. These channels mediate calcium influx in response to membrane depolarization and are expressed in neurons, cardiac pacemaker cells, and endocrine cells. Cav1.3 channels have unique properties including low-voltage activation and prolonged current kinetics.
Cav1.3 is a large transmembrane protein consisting of:
Cav1.3 channels play important roles in:
Unlike other L-type channels (Cav1.2), Cav1.3 activates at more negative voltages and shows slower inactivation, making it particularly important for neuronal signaling at near-threshold potentials.
Gain-of-function mutations in CACNA1D have been associated with PD risk. Increased calcium influx through Cav1.3 channels may contribute to dopaminergic neuron vulnerability through:
Cav1.3 dysregulation contributes to calcium homeostasis alterations in AD. Altered channel function may affect amyloid processing and tau pathology.
Motor neurons show altered Cav1.3 expression, potentially contributing to excitotoxic vulnerability.
Gain-of-function mutations cause constitutive channel activity, leading to increased aldosterone secretion.
Current therapeutic approaches include:
[1] Cav1.3 calcium channels and neuronal survival. Cell Calcium. 2014.[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013.[3] Calcium channel blockers in PD therapy. Neuropharmacology. 2015.
CACNA1D channels are regulated by multiple mechanisms:
Gain-of-function mutations in CACNA1D cause:
Loss-of-function variants are associated with:
| Drug | Mechanism | Status |
|---|---|---|
| Dihydropyridines (nifedipine, amlodipine) | L-type channel blockers | Approved |
| Verapamil, diltiazem | Non-dihydropyridine CCBs | Approved |
| BTZ-043 | Specific Cav1.3 blocker | Research |
| CaV1.3-selective compounds | ReduceRunner selectivity | Preclinical |
The study of Cacna1D Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cav1.3 calcium channels and neuronal survival. Cell Calcium. 2014.[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013.[3] Calcium channel blockers in PD therapy. Neuropharmacology. 2015.